A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

计划入组 4 人 · 首次发布于 2012 年 8 月 30 日

Ranolazine in Ischemic Cardiomyopathy

计划入组 28 人 · 首次发布于 2011 年 4 月 29 日

Kaneka Endovascular Embolization and Protection

计划入组 164 人 · 首次发布于 2022 年 10 月 3 日

agatolimod + Nanoxan

LANEX-DCR

Cancer vaccines(Anixa)

Nanexa AB

Sweden

Natera

United States

NANHUA UNIVERSITY

Taiwan

Moderna Partners with Nanexa on PharmaShell Drug Delivery Technology in $500M Deal

Nanexa's NEX-22 Shows Promise as Once-Monthly GLP-1 Therapy in Phase I Trial

Signatera MRD Test Demonstrates Clinical Utility in Colorectal and Breast Cancer Studies